SEC Form 4 · accession 0001144204-16-106842
Altimmune, Inc. · ALT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey W. Runge
Director
Period of report
Jun 1, 2016
Accepted (ET)
Jun 3, 2016 · 5:32 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001326190
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F1 | $2.20 | Jun 1, 2016 | A | 20,000 | A | Jun 1, 2017 | May 31, 2026 | Common Stock | 20,000 | 20,000 | D |
Explanation of responses
- F1This award may be subject to acceleration in certain circumstances.